Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

ACCG-2671

Stage Phase 1/2Stale

Sponsor Aconcagua Bio, Inc

Route oral

Class Amylin

Mechanism nonpeptide dual amylin and calcitonin receptor agonist

Sources

registry, as of 2026-09-14Stale

https://clinicaltrials.gov/study/NCT07815678

First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671. Overall status RECRUITING. Phases PHASE1,PHASE2. Lead sponsor Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics. Enrollment 164. Conditions Obesity. This first-in-human study will evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of ACCG-2671. It will also evaluate the effect of food on the pharmacokinetics, safety, and tolerability of a single dose. Parts 1 and 2 will enroll

ClinicalTrials.gov NCT07815678 protocol and results modules

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT07815678

and Part 3 will enroll otherwise healthy participants with obesity. ACCG-2671 is a nonpeptide dual amylin and calcitonin receptor agonist (DACRA) This study comprises 3 parts: Part 1 (Single Ascending Dose \[SAD\]) will be conducted in healthy participants to assess the safety, tolerability, and PK profile of a sing

NCT07815678 description or intervention text

Studies

First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671

Registry NCT07815678

Phase Phase 1/2

Status Recruiting

Enrollment 164

Start 2025-12-29

Part 1 (SAD)

Comparator placebo

Population Obesity

Placebo Part 1 (SAD)

Population Obesity

Part 2 (Food-effect)

Comparator placebo

Population Obesity

ACCG-2671 Part 3 (MAD)

Comparator placebo

Population Obesity

Placebo Part 3 (MAD)

Population Obesity